The contraceptive drugs and devices market is expected to register a CAGR of 7.92% during the forecast period.
The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of the pandemic. For instance, according to an article published in Contraceptives and Reproductive Medicine in March 2022, it has been observed that the use of long-acting contraceptives decreased, with implants by 76%, intrauterine systems by 79%, and intrauterine devices by 76%. Similarly, according to United Nations Population Fund, in March 2021, women had difficulty accessing contraception nine times, resulting in an almost doubling of unexpected births, from 1.3% pre-lockdown to 2.1% post-lockdown. Thus, there was a significant impact on the contraceptive drugs and devices market due to the COVID-19 pandemic. However, since the lockdown restrictions were lifted, the industry has been recovering well. For instance, in October 2022, TTK Healthcare Ltd in India reported a more than twofold increase in quarterly profit, boosted by increased sales of medical devices and contraceptives. Revenue from its protective devices division, which includes the Skore condom brand, increased by over 33% as new items were introduced. It also received a contract to deliver contraceptive devices to an international organization until July 2023. Such instances are expected to boost the growth of the market over the forecast period.
Certain factors that are propelling the market growth are increasing incidences of sexually transmitted diseases, an increasing rate of unintended pregnancies, and rising government initiatives. Unwanted pregnancies are becoming more prevalent globally and are a major cause for concern. For instance, according to the United Nations Population Fund, in March 2022, unintended pregnancies accounted for about half of all pregnancies worldwide, with 121 million occurring each year. As per the same source, over 60% of unplanned pregnancies end in abortion, with an estimated 45% of all abortions being unsafe, resulting in 5%-13% of all maternal fatalities, putting the world's capacity to meet the 'Sustainable Development Goals' at risk. Additionally, according to the article published in the BMC Pregnancy and Childbirth 2021, unintended pregnancies affect approximately 85 million women worldwide, with India accounting for more than one in every seven of these cases. In addition, as per the same source, Uttar Pradesh, India's most populous state (population of approximately 200 million), has twice the unwanted fertility rate as compared to the rest of the country. Thus, the rising number of unintended pregnancies is expected to boost the demand for contraceptive drugs and devices, which is anticipated to boost market growth over the forecast period.
In addition, the rising prevalence of sexually transmitted diseases among the population is expected to increase the market growth. For instance, according to the report published by the Centers for Disease Control and Prevention in April 2022, it reported that around 133,945 cases of all stages of Syphilis were noted, which includes 41,655 cases of primary and secondary Syphilis, which is considered the most infectious stages of the disease. It also reported an increase of 6.8% in Syphilis in 2020. Additionally, according to the data published by the World Health Organization in November 2021, it has been observed that around 374 million new infections with one of four sexually transmitted diseases - chlamydia (129 million), gonorrhea (82 million), Syphilis (7.1 million) and trichomoniasis (156 million) were recorded in 2020. Thus, the rising burden of sexually transmitted diseases is expected to increase the demand for contraception to avoid getting diseases, thereby propelling market growth.
Furthermore, the countries and their governments have recognized the need to curb the increase in unplanned pregnancies and have launched numerous campaigns to educate people and prevent the spread of unplanned pregnancies and abortions. The usage of contraceptive pills is one of them. The fundamental right to privacy guaranteed by the United States Constitution includes the freedom to obtain and use contraceptives. For instance, the United States Agency for International Development (USAID) promotes and supports voluntary family planning and reproductive health initiatives in approximately 40 countries worldwide. Additionally, in March 2022, National Chlamydia Screening Program (NCSP) was organized in the United Kingdom. The program's main aim is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time to test results and treatment and re-testing after treatment. The program is also changing from prevention and control to focusing on reducing the harms of untreated chlamydia infection by primarily screening women and girls. Thus, government initiatives are also promoting the use of contraceptive methods to avoid unnecessary births and abortions.
Thus, all aforementioned factors, such as rising in the prevalence of sexually transmitted diseases and government initiatives, are expected to propel the growth of the market. However, the high cost of devices and treatment and side effects associated with the use of contraceptive drugs and devices are some of the factors that are likely to impede market growth over the forecast period.
The rising adoption of contraceptive drugs and devices is the key factor driving the demand for the female contraceptive segment, thereby fueling market growth. For instance, according to an article published by the Journal of Family Medicine and Primary Care in June 2021, the contraceptive prevalence rate was found to be 75%. The most used female contraceptive methods were tubectomy (81.6%), intrauterine devices (6.3%), and oral contraceptive pills (0.7%). Thus, the increasing adoption of contraceptive drugs and devices is expected to propel market growth over the forecast period.
The increasing company focus on adopting various business strategies such as product launches, mergers, and company spin-offs is likely to boost the growth of the market over the forecast period. For instance, In April 2022, Lupin, a Mumbai-based pharmaceutical company, launched Merzee capsules, a pregnancy prevention medication, under an exclusive license, marketing, and distribution deal with Slayback Pharma LLC. Additionally, in November 2021, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Quebec under the Régie de l'assurance Maladie du Québec (RAMQ). Similarly, in June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences, is conducting a phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety, and tolerability.
Thus, the above-mentioned factors, such as an increase in the adoption of female contraceptives and product launches, are expected to boost the growth of the segment over the forecast period.
A large section of the women population represents the reproductive age in the United States as well as Canada. Thus, the rising incidences of unwanted pregnancies and abortion rates are the key factor driving the market growth in the region. For instance, according to the statistics published by Pew Research Center in June 2022, it has been observed that the 930,160 abortions recorded in 2020 increased compared to the previous year. Thus, the rising number of abortion cases in the country is expected to increase the demand for adopting various contraceptive methods to avoid unwanted pregnancies, thereby propelling market growth.
In addition, the rising number of sexually transmitted diseases among the population in the region is also contributing to the growth of the market in the region. For instance, in April 2022, a report published by the CDC stated that STDs remain a significant public health concern in the United States. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020, with a total of 1,579,885 cases reported to the CDC. In addition, as per the same source, 677,769 different gonorrhea infections were reported in the United States in 2020. Thus, the rising burden of these diseases among the population is expected to increase the demand for male condoms, which protect against pathogens such as gonorrhea, herpes simplex virus (HSV), hepatitis B, HIV, and chlamydia which are expected to propel the market growth in the region over the forecast period.
Furthermore, several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities and enable women and girls to be in control of their contraceptive care.
Moreover, the increasing contraceptive product approval and launches in the region are also expected to boost market growth over the forecast period. For instance, In June 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals launched Estelle under the trademark Nextstellis (drospirenone and estetrol tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action, in the United States. Also, in March 2021, Mithra and Searchlight Pharma received Health Canada approval for Nextstellis, a combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4) in Canada.
Thus, the above-mentioned factors, such as strategic initiatives coupled with product launches, are expected to boost the growth of the market studied in the country.
This product will be delivered within 2 business days.
The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of the pandemic. For instance, according to an article published in Contraceptives and Reproductive Medicine in March 2022, it has been observed that the use of long-acting contraceptives decreased, with implants by 76%, intrauterine systems by 79%, and intrauterine devices by 76%. Similarly, according to United Nations Population Fund, in March 2021, women had difficulty accessing contraception nine times, resulting in an almost doubling of unexpected births, from 1.3% pre-lockdown to 2.1% post-lockdown. Thus, there was a significant impact on the contraceptive drugs and devices market due to the COVID-19 pandemic. However, since the lockdown restrictions were lifted, the industry has been recovering well. For instance, in October 2022, TTK Healthcare Ltd in India reported a more than twofold increase in quarterly profit, boosted by increased sales of medical devices and contraceptives. Revenue from its protective devices division, which includes the Skore condom brand, increased by over 33% as new items were introduced. It also received a contract to deliver contraceptive devices to an international organization until July 2023. Such instances are expected to boost the growth of the market over the forecast period.
Certain factors that are propelling the market growth are increasing incidences of sexually transmitted diseases, an increasing rate of unintended pregnancies, and rising government initiatives. Unwanted pregnancies are becoming more prevalent globally and are a major cause for concern. For instance, according to the United Nations Population Fund, in March 2022, unintended pregnancies accounted for about half of all pregnancies worldwide, with 121 million occurring each year. As per the same source, over 60% of unplanned pregnancies end in abortion, with an estimated 45% of all abortions being unsafe, resulting in 5%-13% of all maternal fatalities, putting the world's capacity to meet the 'Sustainable Development Goals' at risk. Additionally, according to the article published in the BMC Pregnancy and Childbirth 2021, unintended pregnancies affect approximately 85 million women worldwide, with India accounting for more than one in every seven of these cases. In addition, as per the same source, Uttar Pradesh, India's most populous state (population of approximately 200 million), has twice the unwanted fertility rate as compared to the rest of the country. Thus, the rising number of unintended pregnancies is expected to boost the demand for contraceptive drugs and devices, which is anticipated to boost market growth over the forecast period.
In addition, the rising prevalence of sexually transmitted diseases among the population is expected to increase the market growth. For instance, according to the report published by the Centers for Disease Control and Prevention in April 2022, it reported that around 133,945 cases of all stages of Syphilis were noted, which includes 41,655 cases of primary and secondary Syphilis, which is considered the most infectious stages of the disease. It also reported an increase of 6.8% in Syphilis in 2020. Additionally, according to the data published by the World Health Organization in November 2021, it has been observed that around 374 million new infections with one of four sexually transmitted diseases - chlamydia (129 million), gonorrhea (82 million), Syphilis (7.1 million) and trichomoniasis (156 million) were recorded in 2020. Thus, the rising burden of sexually transmitted diseases is expected to increase the demand for contraception to avoid getting diseases, thereby propelling market growth.
Furthermore, the countries and their governments have recognized the need to curb the increase in unplanned pregnancies and have launched numerous campaigns to educate people and prevent the spread of unplanned pregnancies and abortions. The usage of contraceptive pills is one of them. The fundamental right to privacy guaranteed by the United States Constitution includes the freedom to obtain and use contraceptives. For instance, the United States Agency for International Development (USAID) promotes and supports voluntary family planning and reproductive health initiatives in approximately 40 countries worldwide. Additionally, in March 2022, National Chlamydia Screening Program (NCSP) was organized in the United Kingdom. The program's main aim is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time to test results and treatment and re-testing after treatment. The program is also changing from prevention and control to focusing on reducing the harms of untreated chlamydia infection by primarily screening women and girls. Thus, government initiatives are also promoting the use of contraceptive methods to avoid unnecessary births and abortions.
Thus, all aforementioned factors, such as rising in the prevalence of sexually transmitted diseases and government initiatives, are expected to propel the growth of the market. However, the high cost of devices and treatment and side effects associated with the use of contraceptive drugs and devices are some of the factors that are likely to impede market growth over the forecast period.
Contraceptives Drugs Devices Market Trends
Female Segment is Expected to Hold a Significant Market Share in the Contraceptive Drugs and Devices Market Over the Forecast Period
The female segment in the contraceptive drugs and devices market is expected to witness significant growth over the forecast period owing to the increased adoption of contraceptive drugs and devices, rising sexually transmitted diseases, and a growing number of unintended pregnancies.The rising adoption of contraceptive drugs and devices is the key factor driving the demand for the female contraceptive segment, thereby fueling market growth. For instance, according to an article published by the Journal of Family Medicine and Primary Care in June 2021, the contraceptive prevalence rate was found to be 75%. The most used female contraceptive methods were tubectomy (81.6%), intrauterine devices (6.3%), and oral contraceptive pills (0.7%). Thus, the increasing adoption of contraceptive drugs and devices is expected to propel market growth over the forecast period.
The increasing company focus on adopting various business strategies such as product launches, mergers, and company spin-offs is likely to boost the growth of the market over the forecast period. For instance, In April 2022, Lupin, a Mumbai-based pharmaceutical company, launched Merzee capsules, a pregnancy prevention medication, under an exclusive license, marketing, and distribution deal with Slayback Pharma LLC. Additionally, in November 2021, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Quebec under the Régie de l'assurance Maladie du Québec (RAMQ). Similarly, in June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences, is conducting a phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety, and tolerability.
Thus, the above-mentioned factors, such as an increase in the adoption of female contraceptives and product launches, are expected to boost the growth of the segment over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to dominate the contraceptive drugs and devices market over the forecast period owing to the factors such as the rising cases of unwanted pregnancies and high abortion rates, the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive drugs and devices, and the rising number of government initiatives.A large section of the women population represents the reproductive age in the United States as well as Canada. Thus, the rising incidences of unwanted pregnancies and abortion rates are the key factor driving the market growth in the region. For instance, according to the statistics published by Pew Research Center in June 2022, it has been observed that the 930,160 abortions recorded in 2020 increased compared to the previous year. Thus, the rising number of abortion cases in the country is expected to increase the demand for adopting various contraceptive methods to avoid unwanted pregnancies, thereby propelling market growth.
In addition, the rising number of sexually transmitted diseases among the population in the region is also contributing to the growth of the market in the region. For instance, in April 2022, a report published by the CDC stated that STDs remain a significant public health concern in the United States. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020, with a total of 1,579,885 cases reported to the CDC. In addition, as per the same source, 677,769 different gonorrhea infections were reported in the United States in 2020. Thus, the rising burden of these diseases among the population is expected to increase the demand for male condoms, which protect against pathogens such as gonorrhea, herpes simplex virus (HSV), hepatitis B, HIV, and chlamydia which are expected to propel the market growth in the region over the forecast period.
Furthermore, several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities and enable women and girls to be in control of their contraceptive care.
Moreover, the increasing contraceptive product approval and launches in the region are also expected to boost market growth over the forecast period. For instance, In June 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals launched Estelle under the trademark Nextstellis (drospirenone and estetrol tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action, in the United States. Also, in March 2021, Mithra and Searchlight Pharma received Health Canada approval for Nextstellis, a combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4) in Canada.
Thus, the above-mentioned factors, such as strategic initiatives coupled with product launches, are expected to boost the growth of the market studied in the country.
Contraceptives Drugs Devices Market Competitor Analysis
The Contraceptive Drugs and Devices Market is fragmented and consists of several major players. Over the forecast period, most domestic and international players focus on the emerging market, and these countries are growing rapidly in the contraceptive drugs and devices market. Some of the companies which are currently dominating the market are Bayer AG, Pfizer Inc., Merck & Co. Inc., Teva Pharmaceuticals Ltd, Agile Therapeutics, Allergan PLC, Ani Pharmaceuticals Inc., Church & Dwight Co. Inc., Fuji Latex Co. Ltd, and Johnson & Johnson Ltd.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value in USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Pfizer Inc.
- Organon
- Teva Pharmaceuticals Ltd
- Agile Therapeutics
- AbbVie (Allergan PLC)
- Ani Pharmaceuticals Inc.
- Church & Dwight Co. Inc.
- Fuji Latex Co. Ltd
- Johnson & Johnson Ltd
- Reckitt Benckiser
Methodology
LOADING...
